<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15138">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02149108</url>
  </required_header>
  <id_info>
    <org_study_id>1199.52</org_study_id>
    <secondary_id>2012-000095-42</secondary_id>
    <nct_id>NCT02149108</nct_id>
  </id_info>
  <brief_title>Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer</brief_title>
  <official_title>A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Colorectal Cancer Refractory to Standard Therapies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Australia: Dept of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Austria: Austrian Medicines and Medical Devices Agency</authority>
    <authority>Belgium: Federal Agency for Medicinal and Health Products</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>France: Agence Nationale sécurité médicament et des produits santé</authority>
    <authority>Germany:</authority>
    <authority>Hong Kong:</authority>
    <authority>Israel: Israeli Health Ministry Pharmaceutical Administration</authority>
    <authority>Italy:</authority>
    <authority>Japan:</authority>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <authority>Luxembourg:</authority>
    <authority>Mexico:</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Poland: Registration Medicinal Product Medical Device Biocidal Product</authority>
    <authority>Portugal: National Pharmacy and Medicines Institute</authority>
    <authority>Russia: Pharmacological Committee, Ministry of Health</authority>
    <authority>Spain: Spanish Agency of Medicines and Medical Devices</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Taiwan : Food and Drug Administration</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients
      with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard
      chemotherapy and biological agents.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary endpoint is progression free survival (PFS)</measure>
    <time_frame>22 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Key secondary endpoint is Overall survival (OS)</measure>
    <time_frame>22 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumour response</measure>
    <time_frame>22 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control</measure>
    <time_frame>22 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">764</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Nintedanib (BIBF 1120) + BSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + BSC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nindetanib (BIBF 1120)</intervention_name>
    <arm_group_label>Nintedanib (BIBF 1120) + BSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo + BSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BSC</intervention_name>
    <arm_group_label>Placebo + BSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BSC</intervention_name>
    <arm_group_label>Nintedanib (BIBF 1120) + BSC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age &gt;= 18 years

          -  Signed informed consent

          -  Histologically or cytologically confirmed colorectal adenocarcinoma

          -  Metastatic or locally advanced disease not amenable to curative surgery and/or
             radiotherapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status = 1

          -  At least one measurable lesion according to Response Evaluation Criteria In Solid
             Tumours (RECIST) version 1.1

          -  Progression on standard therapies or withdrawn from standard treatment due to
             unacceptable toxicity. Previous standard treatment must include all of the following:

          -  - fluoropyrimidine

          -  - oxaliplatin: Patients treated with oxalipatin in adjuvant setting should have
             progressed within 6 months of completion of adjuvant therapy or they must have been
             treated with oxaliplatin for metastatic disease

          -  -  irinotecan

          -  -  bevacizumab or aflibercept

          -  - cetuximab or panitumumab for patients with K-Ras wt or Ras wt tumours

          -  - previous treatment with regorafenib is allowed

          -  - Life expectancy of at least 12 weeks

          -  -  Hepatic function: aspartate aminotransferase (AST)/ Alanine Amino Tranferase (ALT)
             = 1.5 X Upper Limit of Normal (ULN) and bilirubin = ULN for patients without liver
             metastases. AST/ALT = 2.5 X ULN and bilirubin = ULN for patients with liver
             metastases. Patients with Gilbert syndrome and bilirubin &lt; 2 X ULN and normal AST/ALT
             are eligible

          -  Coagulation parameters: International normalised ratio (INR) &lt; 2 and prothrombin Time
             (PTT) = 2xULN

        Exclusion criteria:

          -  Previous treatment with nintedanib

          -  toxicity attributed to previous anticancer therapy that did not resolve to Common
             Terminology Criteria for Adverse Events (CTCAE)  grade =1

          -  History of other malignancies in the last 5 years, in particular those that could
             interfere with interpretation of results.

          -  Serious concomitant disease or medical condition affecting compliance with trial
             requirements or which are considered relevant for the evaluation of the efficacy or
             safety of the trial drug,

          -  Significant cardiovascular diseases

          -  History of severe haemorrhagic or thromboembolic event in the past 12 months

          -  Bleeding or thrombotic disorders requiring anticoagulant therapy such as warfarin, or
             similar agents requiring therapeutic INR monitoring

          -  Gastrointestinal disorders or abnormalities that would interfere with absorption of
             study drug

          -  Patient with brain metastases that are symptomatic and/or require therapy.

          -  Patients of childbearing potential who are sexually active and unwilling to use a
             highly effective method of contraception

          -  Pregnancy or breast-feeding.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>May 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
